Bedinvetmab Explained

Type:mab
Mab Type:mab
Target:Nerve growth factor (NGF)
Tradename:Librela
Dailymedid:Bedinvetmab
Routes Of Administration:Subcutaneous
Atcvet:yes
Atc Prefix:N02
Atc Suffix:BG91
Legal Ca:Rx-only
Legal Ca Comment:[1] [2]
Legal Us:Rx-only
Legal Us Comment:[3]
Legal Eu:Rx-only
Legal Eu Comment:[4]
Cas Number:2171034-69-6
Unii:1AY63T2BE2

Bedinvetmab, sold under the brand name Librela is a canine monoclonal antibody used for the control of pain associated with osteoarthritis in dogs.[5] Librela is sponsored by Zoetis.

The most common side effects include increased blood urea nitrogen (an indicator of kidney function), urinary tract infection, bacterial skin infection, skin irritation (dermatitis), rash (erythema) or pain at injection site, vomiting (emesis), and weight loss (anorexia).

Bedinvetmab was approved for medical use in the European Union in November 2020, and in the United States in May 2023.[6] Bedinvetmab is the first monoclonal antibody approved in the United States for controlling osteoarthritis pain in dogs.

Medical uses

Bedinvetmab is indicated for the alleviation of pain associated with osteoarthritis in dogs.

History

Two field studies were conducted to evaluate the effectiveness of bedinvetmab – one in the United States[7] and one in the European Union. Both studies enrolled client-owned dogs diagnosed with osteoarthritis. Half the dogs received bedinvetmab and half the dogs received a sterile saline injection every 28 days for a total of three doses. Before treatment and on various days throughout the study, owners used the Canine Brief Pain Inventory (CBPI) assessment tool to measure the severity of the dog's pain and the degree to which the pain interfered with the dog's daily activities. The weight of evidence from the two field studies demonstrated that bedinvetmab is effective at controlling pain associated with osteoarthritis in dogs when at least two doses are given 28 days apart.

Society and culture

Names

Bedinvetmab is the international nonproprietary name.[8]

Further reading

Notes and References

  1. Web site: Librela Product information . Health Canada .
  2. Web site: Health product highlights 2021: Annexes of products approved in 2021 . . 3 August 2022 . 25 March 2024.
  3. Web site: NADA 141-562 . Librela (bedinvetmab injection) Injectable Solution Dogs . Zoetis Inc. . U.S. Food and Drug Administration .
  4. Web site: Librela EPAR . European Medicines Agency (EMA) . 21 February 2022 . 13 May 2023 . 16 March 2023 . https://web.archive.org/web/20230316043828/https://www.ema.europa.eu/en/medicines/veterinary/EPAR/librela . live .
  5. Web site: FDA Approves First Monoclonal Antibody for Dogs with Osteoarthritis Pain . U.S. Food and Drug Administration (FDA) . 5 May 2023 . 13 May 2023.
  6. Zoetis Announces U.S. FDA Approval of Librela (bedinvetmab injection) to Control Osteoarthritis (OA) Pain in Dogs . Zoetis . Business Wire . 5 May 2023 . 13 May 2023 . 6 May 2023 . https://web.archive.org/web/20230506023701/http://www.businesswire.com/news/home/20230505005475/en/Zoetis-Announces-U.S.-FDA-Approval-of-Librela%E2%84%A2-bedinvetmab-injection-to-Control-Osteoarthritis-OA-Pain-in-Dogs/ . live .
  7. Krautmann M, Walters R, Cole P, Tena J, Bergeron LM, Messamore J, Mwangi D, Rai S, Dominowski P, Saad K, Zhu Y, Guillot M, Chouinard L . Laboratory safety evaluation of bedinvetmab, a canine anti-nerve growth factor monoclonal antibody, in dogs . Veterinary Journal . 276 . 105733 . October 2021 . 34391918 . 10.1016/j.tvjl.2021.105733 . free .
  8. ((World Health Organization)) . 2019 . International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 82 . WHO Drug Information . 33 . 3 . 10665/330879 . free . World Health Organization .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Bedinvetmab".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2025, A B Cryer, All Rights Reserved. Cookie policy.